rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Nancy A. Simonian

Director

Company insider

Files Form 4 as: Director, Generate Biomedicines; President & CEO, Syros Pharmaceuticals; Director, Seagen; Director, Evelo Biosciences; Director, Arqule; Chief Medical Officer, Millennium Pharmaceuticals.

Every Form 4 they filed

In numbers

Trades disclosed
143
Buys
0
Sells
8
Bought
$0
Sold
$2.1M
Companies
6
Companies where not an officer
4
First trade
12 May 2006
Last trade
26 Feb 2026
Last filed
2 Mar 2026

Companies traded

Where they are an officer
Syros PharmaceuticalsDirector, Officer · last 2 Dec 20240 buys · 2 sells
Millennium PharmaceuticalsOfficer · last 14 May 20080 buys · 6 sells
Everywhere else they filed: board seats, 10% stakes, other companies
GENB Generate BiomedicinesDirector · Biotechnology · last 26 Feb 20260 buys · 0 sells
SeagenDirector · last 14 Dec 20230 buys · 0 sells
Evelo BiosciencesDirector · last 17 Jun 20200 buys · 0 sells
ArquleDirector · last 13 May 20100 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
10Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
26 Feb 2026filed 2 Mar 2026GENB Generate Biomedicinesoption or derivative · BiotechnologySEC FORM 4 Code A—29,561 at $0.00filing
26 Feb 2026filed 2 Mar 2026GENB Generate Biomedicinesoption or derivative · BiotechnologySEC FORM 4 Code A—29,561 at $0.00filing
2 Dec 2024filed 4 Dec 2024Syros PharmaceuticalsSEC FORM 4 Sold$10K37,070 at $0.27filing
25 Nov 2024filed 27 Nov 2024Syros PharmaceuticalsSEC FORM 4 Sold$36K134,713 at $0.27filing
31 Oct 2024filed 4 Nov 2024Syros Pharmaceuticalsoption or derivativeSEC FORM 4 Code M—40,125 at $0.00filing
31 Oct 2024filed 4 Nov 2024Syros PharmaceuticalsSEC FORM 4 Code M—40,125filing
5 Jun 2024filed 7 Jun 2024Syros Pharmaceuticalsoption or derivativeSEC FORM 4 Code A—6,000 at $0.00filing
5 Jun 2024filed 7 Jun 2024Syros PharmaceuticalsSEC FORM 4 Code A—4,000 at $0.00filing
1 Apr 2024filed 2 Apr 2024Syros PharmaceuticalsSEC FORM 4 Code F$72K14,052 at $5.12filing
31 Mar 2024filed 2 Apr 2024Syros Pharmaceuticalsoption or derivativeSEC FORM 4 Code M—6,000 at $0.00filing
31 Mar 2024filed 2 Apr 2024Syros Pharmaceuticalsoption or derivativeSEC FORM 4 Code M—39,566 at $0.00filing
31 Mar 2024filed 2 Apr 2024Syros PharmaceuticalsSEC FORM 4 Code M—6,000filing
31 Mar 2024filed 2 Apr 2024Syros PharmaceuticalsSEC FORM 4 Code M—39,566filing
14 Dec 2023filed 15 Dec 2023Seagenoption or derivativeSEC FORM 4 Code D—8,750filing
14 Dec 2023filed 15 Dec 2023Seagenoption or derivativeSEC FORM 4 Code D—9,260filing
14 Dec 2023filed 15 Dec 2023Seagenoption or derivativeSEC FORM 4 Code D—9,260filing
14 Dec 2023filed 15 Dec 2023Seagenoption or derivativeSEC FORM 4 Code D—9,260filing
14 Dec 2023filed 15 Dec 2023Seagenoption or derivativeSEC FORM 4 Code D—9,260filing
14 Dec 2023filed 15 Dec 2023Seagenoption or derivativeSEC FORM 4 Code D—7,038filing
14 Dec 2023filed 15 Dec 2023Seagenoption or derivativeSEC FORM 4 Code D—3,171filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed8

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.